IPO
IPO
Best Performers
Forthcoming Issues
Closed Issues
New Listings
Current Issues
IPO Performance
IPO News
IPO Analysis
Basis of Allotment
Draft Prospectus
  HOME  >  IPO  >   IPO SNAPSHOT
IPO Snapshot    
Akums Drugs & Pharmaceuticals Ltd.
Issue Open Date 30-Jul-24  
Issue Closing Date 01-Aug-24  
Application Money 100  
Allotment Money  
Price Band 646 - 679  
Minimium Application No. 22  
Issue Size (Shares) 27368151  
Market Lot 1.00  
Objective
a. Repayment/ prepayment of indebtedness of our Company;b. Repayment/ prepayment of indebtedness of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited;c. Funding incremental working capital requirements of our Company;d. Pursuing inorganic growth initiatives through acquisitions; ande. General corporate purposes.
Category No. of Shares No. of Shares Subscription Ratio
  Offered / Reserved Bid For  
Non-Institutional Investors   4068637   171750128   42.21  
Qualified Institutional Buyers   8137276   733117770   90.09  
Retail Individual Investors   2712424   57770020   21.30  
Business Description
Established in 2004, we are a pharmaceutical contract development and manufacturing organization (“CDMO”) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, we own the intellectua
more...
Promoter's Holding
Total Share Capital   121528880  
Offered to Public   27368151  
Promoter's Holding (Pre-Issue)   82.48  
Promoter's Holding (Post-Issue)   75.26  
Address
304 Mohan Place
L S C
Saraswati Vihar

Delhi ,
Delhi ,
110034
Phone: 011- 69041000
Email: cs@akums.net
Website: www.akums.in
Registrar
Link Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai
Listed at
BSE, NSE
Lead Manager
Ambit Pvt Ltd.
Axis Capital Ltd.
Citigroup Global Markets India Pvt Ltd.
ICICI Securities Ltd
Promoters
Akums Master Trust
Sandeep Jain
Sanjeev Jain
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.